Austin, TX, July 23, 2014 (GLOBE NEWSWIRE) -- LDR Holding Corporation (Nasdaq:LDRH), a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, announced today that it will report financial results for the second quarter ended June 30, 2014 after the market close on Wednesday, August 6, 2014. The Company also announced that it will host an investor conference call to discuss the results on the same day at 5:00 PM Eastern Time.
LDR Holding invites all interested parties to join the call by dialing (877) 312-5637 for domestic participants and (253) 237-1149 for international participants. The call will also be broadcast live over the Internet and can be accessed on the Investors section of the Company's website at www.ldr.com.
A telephone replay will be available for two weeks following the call by (855) 859-2056 for domestic participants and (404) 537-3406 for international participants. When prompted, please enter the replay pin number 77571093. For those who are not available to listen to the live webcast, the call will be archived for 90 days on LDR Holding's website.
About LDR Holding Corporation
LDR Holding Corporation is a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders. LDR's primary products are based on its exclusive VerteBRIDGE® fusion and Mobi® non-fusion technology platforms and are designed for applications in the cervical and lumbar spine. These technologies enable products that are less invasive, provide greater intra-operative flexibility, offer simplified surgical techniques and promote improved clinical outcomes for patients as compared to existing alternatives. In August 2013, the Company received approval from the U.S. Food and Drug Administration (FDA) for the Mobi-C® cervical disc replacement device, the first and only cervical disc replacement device to receive FDA approval to treat both one-level and two-level cervical disc disease. For more information regarding LDR Holding, visit www.ldr.com.